These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 29574518

  • 1. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K, Harigane K, Kusayama Y, Tezuka T, Choe H, Inaba Y, Saito T.
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [Abstract] [Full Text] [Related]

  • 2. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
    Ebina K, Noguchi T, Hirao M, Hashimoto J, Kaneshiro S, Yukioka M, Yoshikawa H.
    Osteoporos Int; 2016 Jan; 27(1):351-9. PubMed ID: 26475289
    [Abstract] [Full Text] [Related]

  • 3. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C.
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
    Sugimoto T, Inoue D, Maehara M, Oikawa I, Shigematsu T, Nishizawa Y.
    J Bone Miner Metab; 2019 Jul; 37(4):730-740. PubMed ID: 30523414
    [Abstract] [Full Text] [Related]

  • 5. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 6. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y, Suzuki T, Kato H.
    Arch Osteoporos; 2017 Sep 21; 12(1):80. PubMed ID: 28936606
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.
    Sakai A, Ikeda S, Okimoto N, Matsumoto H, Teshima K, Okazaki Y, Fukuda F, Arita S, Tsurukami H, Nagashima M, Yoshioka T.
    Osteoporos Int; 2014 Sep 21; 25(9):2245-53. PubMed ID: 24899103
    [Abstract] [Full Text] [Related]

  • 8. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 21; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
    Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T.
    Osteoporos Int; 2012 Jun 21; 23(6):1737-45. PubMed ID: 21932114
    [Abstract] [Full Text] [Related]

  • 10. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S.
    J Bone Miner Metab; 2018 Mar 21; 36(2):221-228. PubMed ID: 28293779
    [Abstract] [Full Text] [Related]

  • 11. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E, Ito S, Takai C, Kobayashi D, Nomura Y, Otani H, Abe A, Ishikawa H, Murasawa A, Narita I, Nakazono K.
    Intern Med; 2018 Aug 01; 57(15):2169-2178. PubMed ID: 29607978
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial.
    Fujieda Y, Horita T, Nishimoto N, Tanimura K, Amasaki Y, Kasahara H, Furukawa S, Takeda T, Fukaya S, Matsui K, Tsutsumi A, Furusaki A, Sagawa A, Katayama K, Takeuchi K, Katsumata K, Kurita T, Shane P, Kato M, Oku K, Yasuda S, Takahata M, Iwasaki N, Atsumi T.
    Mod Rheumatol; 2021 May 01; 31(3):593-599. PubMed ID: 32820698
    [Abstract] [Full Text] [Related]

  • 13. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY, Sasaki K, Hayami Y, Ohmura SI, Maeda S, Iwagaitsu S, Naniwa T.
    Arch Osteoporos; 2018 Jun 13; 13(1):67. PubMed ID: 29904824
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.
    Osteoporos Int; 2014 Dec 13; 25(12):2729-41. PubMed ID: 25074351
    [Abstract] [Full Text] [Related]

  • 15. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb 13; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.
    Bone; 2012 Jan 13; 50(1):289-95. PubMed ID: 22061864
    [Abstract] [Full Text] [Related]

  • 17. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
    Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2016 Jan 13; 27(1):21-31. PubMed ID: 25990354
    [Abstract] [Full Text] [Related]

  • 18. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, MOVEST Study Group.
    Osteoporos Int; 2015 Nov 13; 26(11):2685-93. PubMed ID: 26001561
    [Abstract] [Full Text] [Related]

  • 19. Short-term daily teriparatide in patients with rheumatoid arthritis.
    Kaneko T, Okamura K, Yonemoto Y, Okura C, Suto T, Tachibana M, Tamura Y, Inoue M, Chikuda H.
    Mod Rheumatol; 2018 May 13; 28(3):468-473. PubMed ID: 28805099
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H.
    Osteoporos Int; 2014 Dec 13; 25(12):2755-65. PubMed ID: 25082556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.